Treprostinil clinical trials
Also written Tyvaso, Remodulin, UT-15C and UT-15.
How each study uses treprostinil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the treprostinil studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 May 2002 · REMODULIN · NDA 021272 (FDA, Drugs@FDA)
- European Union
- 3 Apr 2020 · Trepulmix · EMEA/H/C/005207 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
99 studies that test it; most in 2017 (9)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2005 | 3 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 7 |
| 2009 | 6 |
| 2010 | 8 |
| 2011 | 1 |
| 2012 | 8 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 9 |
| 2018 | 6 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 3 |
| 2025 | 4 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 71 · Other 28
United Therapeutics (60) · Liquidia Technologies, Inc. (6) · Stanford University (3) · Eli Lilly and Company (2) · Brigham and Women's Hospital (2) · University of Florida (1) · Mayo Clinic (1) · Pharmosa Biopharm Inc. (1)
Often tested with
Tested in the same studies.
Sodium Citrate (1) · Citric Acid (1) · Magnesium Chloride (1) · Insulin Lispro (1) · Iloprost (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 1 in phase 3
Studies that test treprostinil, phase 3 first.
- Nov 2027Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)Phase 3 · United Therapeutics
- Feb 2027A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon AttacksPhase 2 · Liquidia Technologies, Inc.
- May 2027A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral SelexipagPhase 4 · Liquidia Technologies, Inc.
- Jul 2027Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary HypertensionEarly Phase 1 · University of California, San Diego
- Jul 2027Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With HypoxemiaPhase 2 · Bastiaan Driehuys
Studies
Open first, then newest update. How each study uses treprostinil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 99
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseaseEnrolling by invitationPhase 3United TherapeuticsNCT04905693Written as Inhaled Treprostinil
- A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILDRecruitingPhase 3Liquidia Technologies, Inc.NCT07285655Written as L606
- A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral SelexipagRecruitingPhase 4Liquidia Technologies, Inc.NCT07759804Written as LIQ861 (treprostinil) inhalation powder
- Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)RecruitingEarly Phase 1Valley Health SystemNCT07837830Written as Treprostinil
- Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With HypoxemiaRecruitingPhase 2Bastiaan DriehuysNCT07037836Written as Inhaled Treprostinil (Tyvaso Nebulizer)
- A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon AttacksNot yet recruitingPhase 2Liquidia Technologies, Inc.NCT07748000Written as LIQ861 (treprostinil) inhalation powder - Dose Titration Arm
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)RecruitingPhase 3United TherapeuticsNCT05943535Written as Inhaled Treprostinil
- Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney TransplantationRecruitingPhase 1/2Rhode Island HospitalNCT04005469Written as Treprostinil
- Open Label Treprostinil Raynaud's StudyRecruitingPhase 4Brigham and Women's HospitalNCT07112183Written as Oral treprostinil (UT-15C) sustained release tablets
- Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial HypertensionNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07177703Written as Treprostinil
- Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary HypertensionNot yet recruitingEarly Phase 1University of California, San DiegoNCT07116681Written as Inhaled treprostinil
- Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAHRecruitingPhase 3University of ArizonaNCT04062565Written as Treprostinil Injectable Product
- Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial HypertensionRecruitingPhase 4Magdi H. YacoubNCT03835676Written as Treprostinil
- Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisCompletedPhase 3United TherapeuticsNCT05255991Written as Inhaled Treprostinil
- Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)TerminatedPhase 3United TherapeuticsNCT03794583Written as Inhaled treprostinil solution
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisCompletedPhase 3United TherapeuticsNCT04708782Written as Inhaled Treprostinil
- Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary HypertensionCompletedPhase 2University of FloridaNCT03814317Written as Inhaled Treprostinil
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial HypertensionActive, not recruitingPhase 4United TherapeuticsNCT05203510Written as Parenteral Treprostinil
- A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary HypertensionCompletedPhase 2Mayo ClinicNCT05564637Written as Treprostinil
- Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606CompletedPhase 1Pharmosa Biopharm Inc.NCT04041648Written as L606 (Liposomal Treprostinil) Inhalation Solution 51ug
See all 99 studies that test treprostinil →
Given beside what is tested · 2 — treprostinil is usual care or a partner of the new treatment
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy ParticipantsCompletedPhase 1Insmed IncorporatedNCT06193031Written as Tyvaso®
- Effect of BIA 5-1058 on the Steady State Pharmacokinetics of TreprostinilCompletedPhase 1Bial - Portela C S.A.NCT04675944Written as treprostinil
Codes
What other systems call treprostinil · ClinicalTrials.gg INT004347
- MeSH (NLM) C427248treprostinilConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) RUM6K67ESGTREPROSTINILConfirmed FDA, NLM, Wikidata
- RxNorm 343048Confirmed FDA, Wikidata
- Wikidata Q3495231treprostinilConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61983TreprostinilOne source FDA
- DrugBank DB00374One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C427248 | treprostinil | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | RUM6K67ESG | TREPROSTINIL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 343048 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3495231 | treprostinil | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61983 | Treprostinil | One source FDA |
| DrugBank | DB00374 | — | One source Wikidata |
Also registered as treprostinil diolamine (UNII H1FKG90039 · RxNorm 1927409) and treprostinil sodium (UNII 7JZ75N2NT6 · RxNorm 342691).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.